Cardiff Oncology (NASDAQ:CRDF) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.15) by 20 percent. This is a 10 percent increase over losses of $(0.20) per share from the same period last year. The company reported quarterly sales of $41.000 thousand which missed the analyst consensus estimate of $85.000 thousand by 51.76 percent. This is a 62.39 percent decrease over sales of $109.000 thousand the same period last year.